Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 15/20 | 0.69 |
| ▸ | AVPR2 | P30518 | 14/20 | 0.69 |
| ▸ | OXTR | P30559 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5832320 | 0.89 | AVPR1A (0.72) | AVPR1AAVPR2OXTR | |
| SCHEMBL5832232 | 0.82 | AVPR1A (1.00) | AVPR1AAVPR2OXTR | |
| SCHEMBL3571243 | 0.73 | AVPR1A (0.82) | AVPR1AAVPR2OXTR | |
| SCHEMBL5832812 | 0.73 | AVPR1A (0.64) | AVPR1AAVPR2OXTR | |
| SCHEMBL5831620 | 0.73 | AVPR1A (0.64) | AVPR1AAVPR2OXTR | |
| SCHEMBL5832848 | 0.72 | AVPR2 (0.71) | AVPR1AAVPR2 | |
| SCHEMBL15228167 | 0.70 | TSHR (0.57) | — | |
| SCHEMBL27530845 | 0.70 | SMN1; SMN2 (0.79) | AVPR1AAVPR2OXTR | |
| SCHEMBL5117349 | 0.70 | AVPR1A (0.71) | AVPR1AAVPR2OXTR | |
| SCHEMBL931837 | 0.70 | AVPR1A (0.76) | AVPR1AAVPR2OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084164-B2 | Triazole derivative | ASTELLAS PHARMA, INC. (JP) | 2006-08-01 | — | — | US | disclosed |
| US-7034047-B2 | Triazole derivative | ASTELLAS PHARMA, INC. (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20060025461-A1 | Triazole derivative | ASTELLAS PHARMA INC. | 2006-02-02 | — | — | US | disclosed |
| CN-1237055-C | Triazole derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2006-01-18 | — | — | CN | disclosed |
| US-20040214818-A1 | Triazole derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD., MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2004-10-28 | — | — | US | disclosed |
| US-20030216385-A1 | Triazole derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| CN-1429215-A | Triazole derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2003-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214818-A1 | Triazole derivative | SLC18A3, SLC6A3, SLC18A2 | AVPR1A 1088/4885AVPR2 898/4885OXTR 1376/4885 |
| US-20030216385-A1 | Triazole derivatives | SLC18A3, SLC18A2, SLC6A3 | AVPR1A 1049/4885AVPR2 926/4885OXTR 1389/4885 |
| US-20060025461-A1 | Triazole derivative | SLC18A3, SLC6A3, SLC18A2 | AVPR1A 1088/4885AVPR2 898/4885OXTR 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.